Home > Press > Kylin Therapeutics Signs Collaboration with Fort Dodge Animal Health, a Division of Wyeth
Abstract:
Kylin To Use Its pRNA Technology to Help Develop New RNAi Therapeutics to Treat Cancer
Kylin Therapeutics, Inc., a biotechnology company, announced it has signed a collaboration with Fort Dodge Animal Health, a division of Wyeth (NYSE:WYE), to develop new RNAi therapeutics for the treatment of cancer. Under the terms of the three-year contract, Kylin will receive research funding, milestone payments and royalties.
Under this contract, Kylin will use its patented RNA nanoparticle technology called "pRNA" to explore the enormous potential of RNA interference (RNAi) and develop new RNA-based therapeutics for the treatment of cancer. In return for its participation in this effort, Fort Dodge will receive an exclusive license to the pRNA/RNAi therapeutic compounds for the treatment of cancers in companion animals. Kylin will retain rights to the therapies for human use.
"We are delighted to welcome Fort Dodge/Wyeth as Kylin's partner. Our business models are complementary, and the results of this effort will provide valuable data and intellectual property that will mutually serve our core businesses," said J. Eric Davis, J.D., president and CEO of Kylin Therapeutics.
The pRNA technology was developed by Peixuan Guo at Purdue University.
####
About Kylin Therapeutics, Inc.
About Kylin Therapeutics
Kylin ( http://www.kylintherapeutics.com ), which is based at the Purdue Research Park, is a leading biotechnology company focused on delivery and development of RNAi based therapeutics. The company employs its revolutionary RNA nanotechnology platform called "pRNA" to develop the potential of RNA interference (RNAi) to treat many common diseases. Kylin's technology platform has the potential to meet the growing market for treating cancer, HIV and other diseases with RNA-based therapeutics.
About Fort Dodge/Wyeth
Fort Dodge Animal Health is a leading manufacturer and distributor of animal health products for the livestock, companion animal, equine, swine and poultry industries in North America and international markets. Key products include CYDECTIN® Pour-On, QUEST® Gel, the Duramune and Fel-O-Vax® vaccine lines, and West-Nile Innovator® equine vaccines. Fort Dodge is headquartered in Overland Park, Kan.
For more information, please click here
Contacts:
Purdue Research Foundation
Marketing and Communication Contact:
Cynthia Sequin, 765-494-4192 (office)
765-413-6031 (mobile)
Copyright © Business Wire 2007
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
Research partnerships
Researchers’ approach may protect quantum computers from attacks March 8th, 2024
'Sudden death' of quantum fluctuations defies current theories of superconductivity: Study challenges the conventional wisdom of superconducting quantum transitions January 12th, 2024
Development of zinc oxide nanopagoda array photoelectrode: photoelectrochemical water-splitting hydrogen production January 12th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||